Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palatal Obturators | 2 | 2008 | 3 | 0.520 |
Why?
|
| Mouth Neoplasms | 1 | 2012 | 64 | 0.350 |
Why?
|
| Dental Prosthesis Retention | 1 | 2008 | 2 | 0.290 |
Why?
|
| Dental Implants | 1 | 2008 | 11 | 0.280 |
Why?
|
| Dental Impression Technique | 1 | 2008 | 5 | 0.280 |
Why?
|
| Immobilization | 1 | 2008 | 15 | 0.280 |
Why?
|
| Radiosurgery | 1 | 2008 | 84 | 0.260 |
Why?
|
| Maxillofacial Prosthesis | 1 | 2005 | 1 | 0.230 |
Why?
|
| Velopharyngeal Insufficiency | 1 | 2005 | 3 | 0.230 |
Why?
|
| Head and Neck Neoplasms | 1 | 2005 | 93 | 0.210 |
Why?
|
| Diphosphonates | 3 | 2012 | 15 | 0.190 |
Why?
|
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 2 | 2012 | 3 | 0.190 |
Why?
|
| Osteonecrosis | 2 | 2008 | 8 | 0.140 |
Why?
|
| Orbit Evisceration | 1 | 2015 | 1 | 0.120 |
Why?
|
| Orbital Implants | 1 | 2015 | 4 | 0.120 |
Why?
|
| Orbital Neoplasms | 1 | 2015 | 11 | 0.120 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 15 | 0.120 |
Why?
|
| Brachytherapy | 1 | 2015 | 54 | 0.110 |
Why?
|
| Imidazoles | 2 | 2012 | 63 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2012 | 39 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 2065 | 0.110 |
Why?
|
| Humans | 12 | 2015 | 28851 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2012 | 32 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 347 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 2 | 2012 | 18 | 0.100 |
Why?
|
| Tongue Neoplasms | 1 | 2012 | 6 | 0.090 |
Why?
|
| Mouth | 1 | 2012 | 31 | 0.090 |
Why?
|
| Eye Protective Devices | 1 | 2011 | 1 | 0.090 |
Why?
|
| Radiography, Dental | 1 | 2011 | 7 | 0.090 |
Why?
|
| Radiation Protection | 1 | 2011 | 17 | 0.090 |
Why?
|
| Maxilla | 2 | 2008 | 35 | 0.090 |
Why?
|
| Eye | 1 | 2011 | 36 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2011 | 54 | 0.090 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2011 | 41 | 0.090 |
Why?
|
| Male | 7 | 2015 | 13921 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1032 | 0.080 |
Why?
|
| Bacteria | 1 | 2012 | 286 | 0.080 |
Why?
|
| Jaw Neoplasms | 1 | 2008 | 1 | 0.070 |
Why?
|
| Jaw | 1 | 2008 | 4 | 0.070 |
Why?
|
| Jaw Diseases | 1 | 2008 | 4 | 0.070 |
Why?
|
| Denture, Complete, Upper | 1 | 2008 | 1 | 0.070 |
Why?
|
| Maxillary Neoplasms | 1 | 2008 | 2 | 0.070 |
Why?
|
| Dental Prosthesis Design | 1 | 2008 | 5 | 0.070 |
Why?
|
| Osseointegration | 1 | 2008 | 3 | 0.070 |
Why?
|
| Denture Design | 1 | 2008 | 13 | 0.070 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 1 | 0.070 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2008 | 4 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 15 | 0.070 |
Why?
|
| Dental Impression Materials | 1 | 2008 | 3 | 0.070 |
Why?
|
| Acrylic Resins | 1 | 2008 | 13 | 0.070 |
Why?
|
| Fistula | 1 | 2008 | 17 | 0.070 |
Why?
|
| Surface Properties | 1 | 2008 | 134 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 108 | 0.070 |
Why?
|
| Equipment Design | 1 | 2008 | 218 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 336 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 165 | 0.060 |
Why?
|
| Cephalometry | 1 | 2005 | 28 | 0.060 |
Why?
|
| Middle Aged | 4 | 2012 | 7414 | 0.050 |
Why?
|
| Adult | 4 | 2012 | 8024 | 0.050 |
Why?
|
| Aged | 3 | 2012 | 5598 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2015 | 107 | 0.050 |
Why?
|
| Female | 6 | 2012 | 15624 | 0.050 |
Why?
|
| Mandible | 2 | 2012 | 43 | 0.040 |
Why?
|
| Adolescent | 1 | 2005 | 3193 | 0.030 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2015 | 7 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2015 | 36 | 0.030 |
Why?
|
| Proton Therapy | 1 | 2015 | 29 | 0.030 |
Why?
|
| Risk Factors | 2 | 2012 | 2126 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 118 | 0.030 |
Why?
|
| DMF Index | 1 | 2012 | 4 | 0.020 |
Why?
|
| New York City | 1 | 2012 | 18 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 145 | 0.020 |
Why?
|
| Fusobacterium | 1 | 2012 | 2 | 0.020 |
Why?
|
| Porphyromonas | 1 | 2012 | 3 | 0.020 |
Why?
|
| Maxillary Diseases | 1 | 2012 | 2 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2012 | 7 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2012 | 37 | 0.020 |
Why?
|
| Eubacterium | 1 | 2012 | 10 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2012 | 16 | 0.020 |
Why?
|
| Prevotella | 1 | 2012 | 6 | 0.020 |
Why?
|
| Peptostreptococcus | 1 | 2012 | 3 | 0.020 |
Why?
|
| Mandibular Diseases | 1 | 2012 | 7 | 0.020 |
Why?
|
| Streptococcus | 1 | 2012 | 17 | 0.020 |
Why?
|
| Lactobacillus | 1 | 2012 | 14 | 0.020 |
Why?
|
| Radiometry | 1 | 2012 | 45 | 0.020 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 2011 | 2 | 0.020 |
Why?
|
| Lens, Crystalline | 1 | 2011 | 6 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 261 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 31 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 68 | 0.020 |
Why?
|
| Cataract | 1 | 2011 | 26 | 0.020 |
Why?
|
| Biodiversity | 1 | 2012 | 114 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 480 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 327 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 101 | 0.020 |
Why?
|
| Biofilms | 1 | 2012 | 122 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 477 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 215 | 0.020 |
Why?
|
| Phylogeny | 1 | 2012 | 490 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2287 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 15 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 477 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 102 | 0.020 |
Why?
|
| Oroantral Fistula | 1 | 2008 | 1 | 0.020 |
Why?
|
| Oral Fistula | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cutaneous Fistula | 1 | 2008 | 6 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2008 | 28 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 63 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2008 | 106 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1173 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 151 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 686 | 0.020 |
Why?
|
| Brain | 1 | 2011 | 769 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 482 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 2426 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2008 | 2635 | 0.010 |
Why?
|